Puckett Lauren M, Rajkotia Poonam, Coppola Lisa, Baumgartner Lori, Roberts Amity L, Maldonado Yanice, Girotto Jennifer E
J Pediatr Pharmacol Ther. 2021;26(8):802-808. doi: 10.5863/1551-6776-26.8.802. Epub 2021 Nov 10.
Identification of organisms directly from positive blood culture by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) has the potential for improved clinical outcomes through earlier organism identification and shorter time to appropriate clinical intervention. The uses of this technology in pediatric patients and its impact in this patient population have not been well described.
Direct from positive blood culture organism identification via MALDI-TOF was implemented in September 2019. A quality improvement project was performed to assess its impact on admissions for contaminant blood cultures and time to effective and optimal antimicrobials and clinical decision-making. A pre- and post-implementation retrospective review for consecutive September through February time periods, was conducted on patients with positive monomicrobial blood cultures. Statistics were evaluated using Mann-Whitney and χ tests.
One hundred nineteen patients with 131 unique blood cultures (65 in pre- and 66 in post-implementation) were identified. Time to identification was shorter, median 35.4 hours (IQR, 22.7-54.3) versus 42.3 hours (IQR, 36.5-49) in post- and pre-groups, respectively (p = 0.02). Patients were less likely to be admitted for a contaminated blood culture in the post-implementation, 26% versus 11% in the pre-implementation (p = 0.03) group. In patients treated for bacteremia, there was a shorter time to optimal therapy from Gram stain reporting in the post-implementation (median 42.7 hours [IQR, 27.2-72]) versus pre-implementation (median 60.8 hours [IQR, 42.9-80.6]) (p = 0.03).
Direct from positive blood culture identification by MALDI-TOF decreased time to effective and optimal antimicrobials and decreased unnecessary admission in pediatric patients for contaminated blood cultures.
通过基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF MS)直接从阳性血培养物中鉴定微生物,有可能通过更早地鉴定微生物和缩短至适当临床干预的时间来改善临床结果。这项技术在儿科患者中的应用及其对该患者群体的影响尚未得到充分描述。
2019年9月开始通过MALDI-TOF直接从阳性血培养物中鉴定微生物。开展了一项质量改进项目,以评估其对因污染血培养物入院情况、至有效和最佳抗菌药物的时间以及临床决策的影响。对9月至2月期间连续的单微生物阳性血培养患者进行了实施前和实施后的回顾性研究。使用Mann-Whitney检验和χ检验进行统计学评估。
共确定了119例患者的131份独特血培养物(实施前65份,实施后66份)。鉴定时间更短,实施后组的中位数为35.4小时(IQR,22.7-54.3),实施前组为42.3小时(IQR,36.5-49)(p = 0.02)。实施后因污染血培养物入院的患者较少,实施前为26%,实施后为11%(p = 0.03)。在治疗菌血症的患者中,实施后从革兰氏染色报告至最佳治疗的时间更短(中位数42.7小时[IQR,27.2-72]),而实施前为中位数60.8小时[IQR,42.9-80.6])(p = 0.03)。
通过MALDI-TOF直接从阳性血培养物中鉴定微生物,减少了至有效和最佳抗菌药物的时间,并减少了儿科患者因污染血培养物而不必要的入院情况。